{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:13:00Z","timestamp":1773461580206,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-114916"],"award-info":[{"award-number":["MOP-114916"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bcp.2016.03.023","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T22:07:17Z","timestamp":1459462037000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Brain \u03b17 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients"],"prefix":"10.1016","volume":"109","author":[{"given":"Marc","family":"Morissette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H.","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2016.03.023_b0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-138-8-200304150-00013","article-title":"Update on Parkinson disease","volume":"138","author":"Siderowf","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"21 Suppl. 4","key":"10.1016\/j.bcp.2016.03.023_b0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.bcp.2016.03.023_b0015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.bcp.2016.03.023_b0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2019magic\u2019 of L-dopa: why is it the gold standard Parkinson\u2019s disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2016.03.023_b0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2016.03.023_b0030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J. Neurobiol."},{"issue":"5479","key":"10.1016\/j.bcp.2016.03.023_b0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1126\/science.289.5479.633","article-title":"Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function","volume":"289","author":"Kaneko","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2016.03.023_b0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bcp.2015.06.014","article-title":"Alpha7 nicotinic receptors as therapeutic targets for Parkinson\u2019s disease","volume":"97","author":"Quik","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2016.03.023_b0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/bs.irn.2015.07.005","article-title":"Nicotine and nicotinic receptor drugs: potential for Parkinson\u2019s disease and drug-induced movement disorders","volume":"124","author":"Quik","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2016.03.023_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0166-4328(00)00204-7","article-title":"Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness","volume":"113","author":"Nomikos","year":"2000","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.bcp.2016.03.023_b0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/1097-4547(20000901)61:5<533::AID-JNR8>3.0.CO;2-Y","article-title":"Study of the bidirectional transport of choline by blocking choline carriers from outside or inside brain nerve terminals","volume":"61","author":"Marchi","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bcp.2016.03.023_b0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cne.902220208","article-title":"A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)","volume":"222","author":"Szabo","year":"1984","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson\u2019s disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.10031","article-title":"Clinical-pathological study of levodopa complications","volume":"17","author":"Rajput","year":"2002","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/mds.10343","article-title":"Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications","volume":"18","author":"Calon","year":"2003","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.brainres.2003.10.062","article-title":"Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys","volume":"999","author":"Kulak","year":"2004","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.bcp.2016.03.023_b0095","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","article-title":"Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations","volume":"82","author":"Williams","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2016.03.023_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","article-title":"It is not \u201ceither\/or\u201d: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood","volume":"84","author":"Picciotto","year":"2008","journal-title":"Prog. Neurobiol."},{"issue":"11","key":"10.1016\/j.bcp.2016.03.023_b0105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","article-title":"AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys","volume":"20","author":"Di Paolo","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2016.03.023_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.114.216283","article-title":"The alpha7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys","volume":"351","author":"Zhang","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","article-title":"Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys","volume":"186","author":"Gregoire","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.bcp.2016.03.023_b0120","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/mds.20596","article-title":"Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys","volume":"20","author":"Samadi","year":"2005","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jnr.23160","article-title":"3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats","volume":"91","author":"Suzuki","year":"2013","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-120157","article-title":"The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice","volume":"3","author":"Stuckenholz","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bcp.2016.03.023_b0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The alpha7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2016.03.023_b0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2967\/jnumed.113.132068","article-title":"18F-ASEM, a radiolabeled antagonist for imaging the alpha7-nicotinic acetylcholine receptor with PET","volume":"55","author":"Horti","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2016.03.023_b0145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s11307-014-0779-3","article-title":"Human brain imaging of alpha7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy","volume":"16","author":"Wong","year":"2014","journal-title":"Mol. Imaging Biol."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/jm501642c","article-title":"Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases","volume":"58","author":"Jaeschke","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2016.03.023_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1124\/jpet.115.226597","article-title":"VU0477573: Partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy","volume":"356","author":"Nickols","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/jm401622k","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2016.03.023_b0165","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/mds.22721","article-title":"Advances in environmental epidemiology","volume":"25","author":"Tanner","year":"2010","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.bcp.2016.03.023_b0170","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.0b013e3181d55f38","article-title":"Smoking duration, intensity, and risk of Parkinson disease","volume":"74","author":"Chen","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bcp.2016.03.023_b0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/WNL.52.1.115","article-title":"Smoking and Parkinson\u2019s disease: a dose-response relationship","volume":"52","author":"Gorell","year":"1999","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2016.03.023_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0166-4328(00)00210-2","article-title":"Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging","volume":"113","author":"Hellstrom-Lindahl","year":"2000","journal-title":"Behav. Brain Res."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2016.03.023_b0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","article-title":"Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases","volume":"393","author":"Perry","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2016.03.023_b0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0304-3940(99)00473-5","article-title":"Changes with aging and ischemia in nicotinic acetylcholine receptor subunit alpha7 mRNA expression in postmortem human frontal cortex and putamen","volume":"270","author":"Utsugisawa","year":"1999","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2016.03.023_b0195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3233\/JAD-2003-5602","article-title":"Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro","volume":"5","author":"Reid","year":"2003","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.bcp.2016.03.023_b0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.105.093047","article-title":"Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats","volume":"316","author":"Hernandez","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2016.03.023_b0205","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.neuropharm.2014.01.014","article-title":"Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys","volume":"79","author":"Morin","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2016.03.023_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pnpbp.2014.07.006","article-title":"Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys","volume":"56","author":"Morin","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2016.03.023_b0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2016.03.023_b0220","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.neuropharm.2015.08.002","article-title":"Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications","volume":"99","author":"Morin","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2016.03.023_b0225","series-title":"Atlas of the Human Brain","author":"Mai","year":"1997"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216300041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216300041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T01:20:05Z","timestamp":1600392005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216300041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":45,"alternative-id":["S0006295216300041"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.03.023","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain \u03b17 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}